COMPANY PROFILE

Third Arc Bio

Transformational therapies for solid tumors and immune diseases using multifunctional antibodies to precisely activate or inhibit T cells

Lower Gwynedd Township, United StatesFounded 2022Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Third Arc Bio

Third Arc Bio is a biotechnology company focused on developing innovative therapies for solid tumors and immune diseases. The company specializes in creating multifunctional antibodies that form immune synapses, which are structures that allow immune cells to communicate and coordinate their actions. These antibodies are designed to precisely activate or inhibit T cells, a type of immune cell, to target and treat specific diseases.

Third Arc Bio operates in the biopharmaceutical market, primarily serving patients with cancer and immune-related conditions. The company employs a business model centered around research and development, aiming to bring new, effective treatments to market. Revenue is generated through the development and commercialization of these therapies, often in collaboration with larger pharmaceutical companies.

The company's world-class team has a proven track record of success, positioning Third Arc Bio to advance the next generation of highly innovative medicines that redefine the standard of care.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Lower Gwynedd Township, United States
Employees: 42
Open positions: 1
Dealroom signal: 87.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Feb 2026	$52M	$825M	Marshall Wace · T. Rowe Price · Galapagos · Abbvie Biotech Ventures	↗
SERIES AOther financing	Jul 2024	$165M	$660M	BVF Partners · Janus Henderson Investors · ForgePoint Capital · Logos Capital	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Third Arc Bio website traffic

Latest recorded traffic for Third Arc Bio is 6.3K monthly website visits, up 173.9% over the last three months. Third Arc Bio's team grew 20% over the past year.

Latest monthly visits6.3K 3-month web change+173.9% 1-year team growth+20%

Monthly website visitsJul 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SSSecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform	Minneapolis, United States	Operational	19	$17M	$28M
FUFunPepFunPep is an Industry-university collaboration bioventure company	Ibaraki, Japan	Operational
AIArterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors	Atlanta, United States	Operational
LYLysoclearPremium laboratory research services for biotechnology and pharmaceutical companies, specializing in ocular toxicology and structural biology	Lafayette, United States	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ANAmygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction	Palo Alto, United States	Operational
ATAnHeart TherapeuticsPrecision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products	Huangpu, China	Acquired
CBContraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics	Siena, Italy	Operational